First Clinical Experience of 68Ga-FAPI PET/CT in Tertiary Cancer Center: Identifying Pearls and Pitfalls
Diagnostics · 19.01.2025 · 15 (2) · 218
DOI: 10.3390/diagnostics15020218 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 19.01.2025. Verfasst von Akram Al-Ibraheem und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Over the past four years, 68Ga-fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) has been established at a tertiary cancer care facility in Jordan. This retrospective study aims to explore tracer uptake metrics across various epithelial neoplasms, identify diagnostic pitfalls associated with 68Ga-FAPI PET/CT, and evaluate the influence of 68Ga-FAPI PET/CT staging results on changes in therapeutic intent compared to gold standard molecular imaging modalities.
Methods
A total of 48 patients with biopsy-confirmed solid tumors underwent 77 68Ga-FAPI PET/CT examinations for molecular imaging assessment, encompassing neoplasms originating from the gastrointestinal tract, head and neck, hepatobiliary system, pancreas, breast, and lung.
Results
Notably, pancreaticobiliary tumors exhibited the highest tracer uptake, with mean maximum standardized uptake values (SUVmax) and tumor-to-background ratios (TBR) surpassing 10. A comparative sub-analysis of 68Ga-FAPI PET metrics in 20 treatment-naïve patients revealed a significant correlation between 68Ga-FAPI uptake metrics and tumor grade (Spearman’s rho 0.83; p = 0.00001). Importantly, the results from 68Ga-FAPI PET/CT influenced treatment decisions in 35.5% of the cases, primarily resulting in an escalation of management plans. A total of 220 diagnostic challenges were identified across 88.3% of the scans, predominantly within the musculoskeletal system, attributed to degenerative changes (99 observations).
Conclusions
This comprehensive analysis highlights the potential significance of 68Ga-FAPI PET/CT in oncological imaging and treatment strategy, while also emphasizing the necessity for meticulous interpretation to mitigate diagnostic challenges.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan.
- School of Medicine, University of Jordan, Al-Jubeiha, Amman 11942, Jordan.
- Department of Nuclear Medicine, Warith International Cancer Institute, Karbala 56001, Iraq.
- Department of Medicine, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan.
- Department of Radiation Oncology, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan.
- Department of Diagnostic Radiology, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan.
ORCID-Profile: Akram Al-Ibraheem, Ahmed Saad Abdlkadir, Farah Anwar, Issa Mohamad, Asem Mansour
Zitieren
APA
Al-Ibraheem, A., Abdlkadir, A. S., Al-Rasheed, U., Al-Adhami, D., Istatieh, F., Anwar, F., Abdulrahman, M., Amarin, R., Mohamad, I., & Mansour, A. (2025). First Clinical Experience of 68Ga-FAPI PET/CT in Tertiary Cancer Center: Identifying Pearls and Pitfalls. Diagnostics, 15(2), 218. https://doi.org/10.3390/diagnostics15020218
Vancouver
Al-Ibraheem A, Abdlkadir AS, Al-Rasheed U, Al-Adhami D, Istatieh F, Anwar F, et al. First Clinical Experience of 68Ga-FAPI PET/CT in Tertiary Cancer Center: Identifying Pearls and Pitfalls. Diagnostics. 2025;15(2):218. doi:10.3390/diagnostics15020218
BibTeX
@article{AlIbraheem2025,
author = {Al-Ibraheem, Akram and Abdlkadir, Ahmed Saad and Al-Rasheed, Ula and Al-Adhami, Dhuha and Istatieh, Feras and Anwar, Farah and Abdulrahman, Marwah and Amarin, Rula and Mohamad, Issa and Mansour, Asem},
title = {First Clinical Experience of 68Ga-FAPI PET/CT in Tertiary Cancer Center: Identifying Pearls and Pitfalls},
journal = {Diagnostics},
year = {2025},
volume = {15},
number = {2},
pages = {218},
doi = {10.3390/diagnostics15020218}
}
EUVIMED